Prosoma, a pioneering global medical company specializing in Digital Therapeutics (DTx) for oncology, is thrilled to announce a significant funding round aimed at enhancing its innovative solutions. While the exact amount raised remains undisclosed, this funding will be pivotal in advancing the development and deployment of its flagship mobile application, Living Well. Designed to support cancer patients in managing their behavioral and mental health needs, Living Well is clinically validated to improve patients’ quality of life and overall treatment outcomes. This new capital will enable Prosoma to refine its product offerings, enhance user engagement, and expand its reach internationally, thereby solidifying its goal of becoming the global leader in Digital Therapeutics for oncology.
By harnessing cutting-edge technology and medical expertise, Prosoma aims to offer tailored solutions that address the comprehensive needs of cancer patients. Beyond improving individual patient experiences, the application also provides crucial data to pharmaceutical companies and healthcare providers, fostering better treatment outcomes while generating cost savings for healthcare systems. With esteemed partnerships in place for clinical trials and extensive participation in renowned accelerator programs such as Accelerate Cambridge and the HealthHub at the University of California, Prosoma is well-positioned to make a significant impact on the oncology landscape. Adhering to stringent EU Medical Device Regulations, the company remains dedicated to delivering high-quality products that empower patients and enhance their journey through treatment. As we move forward, the future looks brighter for cancer patients worldwide, thanks to Prosoma's commitment to innovation and care.
.png&w=3840&q=75)
